Abstract
Stroke is one of the major causes of mortality and disability in adults in industrialized countries. Despite numerous preclinical studies and clinical trials in the field of cerebral ischemia, no pharmacological agent has been validated in the treatment of acute ischemic, except thrombolysis. Cerebral ischemia is not only a neuronal disease but it affects the entire neurovascular unit. The therapeutic strategy in stroke should be more global and combine preventive approaches, acute phase treatment and long-term care to improve recovery and prevent or treat affective and cognitive post-stroke consequences. There is an imperative need to develop disease-modifying drugs, which should be able to induce neuroprotection, to serve as adjuvants for thrombolysis by decreasing the hemorrhagic risk and to limit the long-term post-stroke consequences. This review presents the potential effects of Peroxisome Proliferator-Activated Receptors (PPARs) and of their agonists in stroke. We focus on each PPAR receptor and detail their implication in stroke. PPARs are nuclear receptors, acting as ligand-dependent transcription factors. They are expressed in the neurovascular unit that suggests that PPARs could play a role in stroke. Indeed, it has been shown that they are able to interfere with pathways implicated in the pathophysiology of stroke. They could be an answer to this disease-modifying drug concept, being able to act on the different phases of ischemia.
Keywords: Disease-modifying drugs, PPAR, stroke.
Current Drug Targets
Title:PPARs: A Potential Target for a Disease-Modifying Strategy in Stroke
Volume: 14 Issue: 7
Author(s): Thavarak Ouk, Camille Potey, Sophie Gautier, Michele Bastide, Dominique Deplanque, Bart Staels, Patrick Duriez, Didier Leys and Regis Bordet
Affiliation:
Keywords: Disease-modifying drugs, PPAR, stroke.
Abstract: Stroke is one of the major causes of mortality and disability in adults in industrialized countries. Despite numerous preclinical studies and clinical trials in the field of cerebral ischemia, no pharmacological agent has been validated in the treatment of acute ischemic, except thrombolysis. Cerebral ischemia is not only a neuronal disease but it affects the entire neurovascular unit. The therapeutic strategy in stroke should be more global and combine preventive approaches, acute phase treatment and long-term care to improve recovery and prevent or treat affective and cognitive post-stroke consequences. There is an imperative need to develop disease-modifying drugs, which should be able to induce neuroprotection, to serve as adjuvants for thrombolysis by decreasing the hemorrhagic risk and to limit the long-term post-stroke consequences. This review presents the potential effects of Peroxisome Proliferator-Activated Receptors (PPARs) and of their agonists in stroke. We focus on each PPAR receptor and detail their implication in stroke. PPARs are nuclear receptors, acting as ligand-dependent transcription factors. They are expressed in the neurovascular unit that suggests that PPARs could play a role in stroke. Indeed, it has been shown that they are able to interfere with pathways implicated in the pathophysiology of stroke. They could be an answer to this disease-modifying drug concept, being able to act on the different phases of ischemia.
Export Options
About this article
Cite this article as:
Ouk Thavarak, Potey Camille, Gautier Sophie, Bastide Michele, Deplanque Dominique, Staels Bart, Duriez Patrick, Leys Didier and Bordet Regis, PPARs: A Potential Target for a Disease-Modifying Strategy in Stroke, Current Drug Targets 2013; 14 (7) . https://dx.doi.org/10.2174/1389450111314070005
DOI https://dx.doi.org/10.2174/1389450111314070005 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Annotations
Recent Patents on Anti-Infective Drug Discovery Black Hole Attack Detection in Healthcare Wireless Sensor Networks Using Independent Component Analysis Machine Learning Technique
Current Signal Transduction Therapy Simvastatin is Protective During Staphylococcus aureus Pneumonia
Current Pharmaceutical Biotechnology Mucoadhesive Buccal Patch Role in Emesis: Tweaked up by the Pivotal Permeation Enhancer: Sodium Lauryl Sulphate
Drug Delivery Letters Editorial [Hot Topic: Angiogenesis Agents (Executive Editor: Cezary Marcinkiewicz)]
Current Pharmaceutical Design A Pilot Study to Assess Adenosine 5’-triphosphate Metabolism in Red Blood Cells as a Drug Target for Potential Cardiovascular Protection
Cardiovascular & Hematological Disorders-Drug Targets Adipose Tissue and the Vessel Wall
Current Drug Targets Cardiovascular Risk Calculators and their Applicability to South Asians
Current Diabetes Reviews Editorial [Hot Topic: Type II Diabetes (Executive Editor: Ulf Smith)]
Current Molecular Medicine A Concise Overview of Biosensing Technologies for the Detection of Alzheimer's Disease Biomarkers
Current Pharmaceutical Biotechnology MicroRNAs in the Diagnosis and Treatment of Unstable Angina
Current Topics in Medicinal Chemistry Pharmacological Inhibition of Voltage-gated Ca<sup>2+</sup> Channels for Chronic Pain Relief
Current Neuropharmacology Elderly Hypertensive Patients: Silent White Matter Lesions, Blood Pressure Variability, Baroreflex Impairment and Cognitive Deterioration
Current Hypertension Reviews Current Perspectives of Healthy Mitochondrial Function for Healthy Neurons
Current Drug Targets Cardiovascular and Hematological Medicine in 2018 – Advances and Insights
Cardiovascular & Hematological Agents in Medicinal Chemistry Development of Patents and Clinical Trials on Regenerative Therapy: Gene Therapy
Recent Patents on Regenerative Medicine Cognitive Assessment of Dementia: The Need for an Inclusive Design Tool
Current Alzheimer Research The Role of T-Helper Cells in Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Daidzein and its Effects on Brain
Current Medicinal Chemistry Features of Undifferentiated Spondyloarthropathy and Juvenile Spondyloarthropathy Among Asian Populations
Current Rheumatology Reviews